Swiss drug development company Relief Therapeutics Holdings SA (Relief Therapeutics)(SWX:RLF) said on 23 September 2020 that along with its US partner NeuroRx, it has asked the US Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, Reuters news agency reported on Wednesday.
Citing a 51-person study, Relief Therapeutics said in a statement: "Patients treated with RLF-100 demonstrated a three-fold advantage in survival, recovery from respiratory failure and other parameters indicative of meaningful clinical improvement."
The company added that the request, if granted, would make the drug, previously used against conditions including erectile dysfunction, available to those in intensive care who have exhausted all approved treatments.
Amgen's UPLIZNA receives US FDA approval
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Zydus Lifesciences enters licence and supply partnership with Formycon
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome